NCT01741844

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence

Regulatory Post Marketing Surveillance of Intelence Tablet

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 57 (actual)
• Sponsor: Janssen Korea, Ltd., Korea · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety data of etravirine in a natural clinical practice.

Detailed description

This is a non-interventional (a scientific study to make a clear and easy understanding of the cause and effect relationship), prospective (in which the participants are first identified and then followed forward as time passes), consecutive survey for collecting safety and efficacy data of etravirine in treatment of Acquired Immune Deficiency Syndrome (AIDS) in a natural clinical practice.

Conditions

• Acquired Immune Deficiency Syndrome

Interventions

Type	Name	Description
DRUG	No intervention	This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).

Timeline

• Start date: 2012-09-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2012-12-05
• Last updated: 2016-04-04

Locations

1 site across 1 country: South Korea